A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Clinical trial NCT03850535 · TERMINATED
Trial details
- NCT number
- NCT03850535
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-25
- Primary completion
- 2020-09-10
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.